We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock

Delisted

VYNT was delisted on the 12th of May, 2023.

36 hedge funds and large institutions have $16.3M invested in Vyant Bio, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

95% more capital invested

Capital invested by funds: $8.33M → $16.3M (+$7.95M)

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

24% more funds holding

Funds holding: 2936 (+7)

47% less call options, than puts

Call options by funds: $31K | Put options by funds: $59K

Holders
36
Holders Change
+7
Holders Change %
+24.14%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
12
Reduced
8
Closed
2
Calls
$31K
Puts
$59K
Net Calls
-$28K
Net Calls Change
-$28K

VYNT Hedge Fund Activity: Q2 2015 in Review

36 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2015, worth a combined $16.3M — up 95% from $8.33M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new VYNT positions and 2 closed out — a net gain of 7 holders — while 12 added to existing stakes and 8 trimmed.

The largest buyer was Allianz Asset Management, opening a new position worth an estimated $1.4M. The largest seller was Sterneck Capital Management, cutting an estimated $381K.

  • 36 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2015, up from 29 in Q1 2015.
  • Funds reported $16.3M of Vyant Bio, Inc. Common Stock stock for Q2 2015, up 95% quarter-over-quarter.
  • 9 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2015 and 2 closed out, a net change of +7 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q2 2015 was Allianz Asset Management, an estimated $1.4M added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q2 2015 was Sterneck Capital Management, an estimated $381K sold.

Based on aggregated 13F filings for Q2 2015.